Coronary interventions

Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS stents for coronary bifurcation treatment: four-year results of the randomised POLBOS I and POLBOS II clinical trials

EuroIntervention 2020;15:1460-1463. DOI: 10.4244/EIJ-D-18-00172

Robert Gil
Robert J. Gil1,2, MD, PhD; Jacek Bil1, MD, PhD; Adam Kern3, MD, PhD; Luis A. Ingio Garcia4, MD; Radoslaw Formuszewicz5, MD; Slawomir Dobrzycki6, MD, PhD; Dobrin Vassilev7, MD, PhD; Agnieszka Segiet8, MSc, PhD
1. Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland; 2. Mossakowski Medical Research Center, Polish Academy of Science, Warsaw, Poland; 3. Department of Cardiology and Cardiosurgery, University of Warmia and Masury, Olsztyn, Poland; 4. Costa del Sol Hospital, Marbella, Spain; 5. 10th Clinical Military Hospital, Bydgoszcz, Poland; 6. Department of Invasive Cardiology, Medical University in Bialystok, Bialystok, Poland; 7. Alexandrovska University Hospital, Sofia, Bulgaria; 8. Warsaw Medical University, Warsaw, Poland


The wide variation in bifurcation anatomy has generated ongoing research for stents designed specifically for coronary bifurcations; results to date have been unsatisfactory1,2. Earlier, we presented 12 months of pooled data from the POLBOS I and II trials ( Identifiers: NCT02192840, NCT02198300)3; the present study extends the follow-up to four years.



The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE) consisting of cardiac death, myocardial infarction (MI), and target lesion revascularisation (TLR) within 48 months. The secondary endpoints were defined in the primary publication3.



Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Coronary interventionsLeft main and multivessel diseaseBifurcation lesions
Read next article
Percutaneous reintervention on aortic coarctation stenting

Latest news